Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B brings in $100mm for eGenesis

Executive Summary

Gene editing company eGenesis Inc. raised $100mm in its Series B financing led by Fresenius Medical Care Ventures, which was joined by other new backers Leaps by Bayer (contributed $50mm and adds two board members) and Wellington Partners, and returning shareholders Arch Venture Partners, Biomatics Capital, Alta Partners, and Khosla Ventures. The financing will help the firm move its kidney xenotransplant program into the clinic and to advance other xenotransplant programs including those involving the liver, heart, lung, and islet cells of the pancreas. The company raised $38mm in its 2017 Series A round.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Transgenics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies